Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis

Koji Kawamura, Takashi Ikeda, Shotaro Hagiwara, Takehiko Mori, Atsushi Shinagawa, Kaichi Nishiwaki, Kazuteru Ohashi, Shiro Kubonishi, Takahiro Fukuda, Toshiro Ito, Naoto Tomita, Tatsuo Ichinohe, Koji Kato, Yasuo Morishima, Yoshiko Atsuta, Kazutaka Sunami, Yoshinobu Kanda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Abstract: Autologous hematopoietic stem cell transplantation (auto-HCT) is considered a standard therapy for transplant-eligible patients with multiple myeloma, while allogeneic HCT (allo-HCT) is controversial. We retrospectively analyzed 765 patients with myeloma who underwent tandem transplantation between 1998 and 2012 using Japanese registry data. We evaluated the clinical outcomes of tandem auto-HCT (n = 676) and auto/allo-HCT (n = 89). To adjust for a selection bias, we compared overall survival (OS) between the two groups by a propensity score analysis. The probability of OS at six years was 58.5% for the tandem auto-HCT group and 54.4% for the tandem auto/allo-HCT group (p = 0.47). In a matched-pair analysis based on the propensity score, the difference in survival between the two groups was not statistically significant, although the survival curve appeared to reach a plateau beyond five years in the auto/allo group. Further strategies to reduce treatment-related mortality and enhance a graft-versus-myeloma effect are necessary to improve OS.

Original languageEnglish
Pages (from-to)2077-2083
Number of pages7
JournalLeukemia and Lymphoma
Volume57
Issue number9
DOIs
Publication statusPublished - Sep 1 2016
Externally publishedYes

Fingerprint

Propensity Score
Autologous Transplantation
Homologous Transplantation
Multiple Myeloma
Hematopoietic Stem Cell Transplantation
Survival
Transplants
Matched-Pair Analysis
Selection Bias
Registries
Transplantation
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kawamura, K., Ikeda, T., Hagiwara, S., Mori, T., Shinagawa, A., Nishiwaki, K., ... Kanda, Y. (2016). Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis. Leukemia and Lymphoma, 57(9), 2077-2083. https://doi.org/10.3109/10428194.2016.1154958

Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma : propensity score analysis. / Kawamura, Koji; Ikeda, Takashi; Hagiwara, Shotaro; Mori, Takehiko; Shinagawa, Atsushi; Nishiwaki, Kaichi; Ohashi, Kazuteru; Kubonishi, Shiro; Fukuda, Takahiro; Ito, Toshiro; Tomita, Naoto; Ichinohe, Tatsuo; Kato, Koji; Morishima, Yasuo; Atsuta, Yoshiko; Sunami, Kazutaka; Kanda, Yoshinobu.

In: Leukemia and Lymphoma, Vol. 57, No. 9, 01.09.2016, p. 2077-2083.

Research output: Contribution to journalArticle

Kawamura, K, Ikeda, T, Hagiwara, S, Mori, T, Shinagawa, A, Nishiwaki, K, Ohashi, K, Kubonishi, S, Fukuda, T, Ito, T, Tomita, N, Ichinohe, T, Kato, K, Morishima, Y, Atsuta, Y, Sunami, K & Kanda, Y 2016, 'Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis', Leukemia and Lymphoma, vol. 57, no. 9, pp. 2077-2083. https://doi.org/10.3109/10428194.2016.1154958
Kawamura, Koji ; Ikeda, Takashi ; Hagiwara, Shotaro ; Mori, Takehiko ; Shinagawa, Atsushi ; Nishiwaki, Kaichi ; Ohashi, Kazuteru ; Kubonishi, Shiro ; Fukuda, Takahiro ; Ito, Toshiro ; Tomita, Naoto ; Ichinohe, Tatsuo ; Kato, Koji ; Morishima, Yasuo ; Atsuta, Yoshiko ; Sunami, Kazutaka ; Kanda, Yoshinobu. / Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma : propensity score analysis. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 9. pp. 2077-2083.
@article{8a266588c05849e9b9807ed8a7123685,
title = "Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis",
abstract = "Abstract: Autologous hematopoietic stem cell transplantation (auto-HCT) is considered a standard therapy for transplant-eligible patients with multiple myeloma, while allogeneic HCT (allo-HCT) is controversial. We retrospectively analyzed 765 patients with myeloma who underwent tandem transplantation between 1998 and 2012 using Japanese registry data. We evaluated the clinical outcomes of tandem auto-HCT (n = 676) and auto/allo-HCT (n = 89). To adjust for a selection bias, we compared overall survival (OS) between the two groups by a propensity score analysis. The probability of OS at six years was 58.5{\%} for the tandem auto-HCT group and 54.4{\%} for the tandem auto/allo-HCT group (p = 0.47). In a matched-pair analysis based on the propensity score, the difference in survival between the two groups was not statistically significant, although the survival curve appeared to reach a plateau beyond five years in the auto/allo group. Further strategies to reduce treatment-related mortality and enhance a graft-versus-myeloma effect are necessary to improve OS.",
author = "Koji Kawamura and Takashi Ikeda and Shotaro Hagiwara and Takehiko Mori and Atsushi Shinagawa and Kaichi Nishiwaki and Kazuteru Ohashi and Shiro Kubonishi and Takahiro Fukuda and Toshiro Ito and Naoto Tomita and Tatsuo Ichinohe and Koji Kato and Yasuo Morishima and Yoshiko Atsuta and Kazutaka Sunami and Yoshinobu Kanda",
year = "2016",
month = "9",
day = "1",
doi = "10.3109/10428194.2016.1154958",
language = "English",
volume = "57",
pages = "2077--2083",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma

T2 - propensity score analysis

AU - Kawamura, Koji

AU - Ikeda, Takashi

AU - Hagiwara, Shotaro

AU - Mori, Takehiko

AU - Shinagawa, Atsushi

AU - Nishiwaki, Kaichi

AU - Ohashi, Kazuteru

AU - Kubonishi, Shiro

AU - Fukuda, Takahiro

AU - Ito, Toshiro

AU - Tomita, Naoto

AU - Ichinohe, Tatsuo

AU - Kato, Koji

AU - Morishima, Yasuo

AU - Atsuta, Yoshiko

AU - Sunami, Kazutaka

AU - Kanda, Yoshinobu

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Abstract: Autologous hematopoietic stem cell transplantation (auto-HCT) is considered a standard therapy for transplant-eligible patients with multiple myeloma, while allogeneic HCT (allo-HCT) is controversial. We retrospectively analyzed 765 patients with myeloma who underwent tandem transplantation between 1998 and 2012 using Japanese registry data. We evaluated the clinical outcomes of tandem auto-HCT (n = 676) and auto/allo-HCT (n = 89). To adjust for a selection bias, we compared overall survival (OS) between the two groups by a propensity score analysis. The probability of OS at six years was 58.5% for the tandem auto-HCT group and 54.4% for the tandem auto/allo-HCT group (p = 0.47). In a matched-pair analysis based on the propensity score, the difference in survival between the two groups was not statistically significant, although the survival curve appeared to reach a plateau beyond five years in the auto/allo group. Further strategies to reduce treatment-related mortality and enhance a graft-versus-myeloma effect are necessary to improve OS.

AB - Abstract: Autologous hematopoietic stem cell transplantation (auto-HCT) is considered a standard therapy for transplant-eligible patients with multiple myeloma, while allogeneic HCT (allo-HCT) is controversial. We retrospectively analyzed 765 patients with myeloma who underwent tandem transplantation between 1998 and 2012 using Japanese registry data. We evaluated the clinical outcomes of tandem auto-HCT (n = 676) and auto/allo-HCT (n = 89). To adjust for a selection bias, we compared overall survival (OS) between the two groups by a propensity score analysis. The probability of OS at six years was 58.5% for the tandem auto-HCT group and 54.4% for the tandem auto/allo-HCT group (p = 0.47). In a matched-pair analysis based on the propensity score, the difference in survival between the two groups was not statistically significant, although the survival curve appeared to reach a plateau beyond five years in the auto/allo group. Further strategies to reduce treatment-related mortality and enhance a graft-versus-myeloma effect are necessary to improve OS.

UR - http://www.scopus.com/inward/record.url?scp=84961218189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961218189&partnerID=8YFLogxK

U2 - 10.3109/10428194.2016.1154958

DO - 10.3109/10428194.2016.1154958

M3 - Article

C2 - 26961137

AN - SCOPUS:84961218189

VL - 57

SP - 2077

EP - 2083

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -